Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: Past, present, and future recommendations

Oncologist

Volumn 12, Issue 9, 2007, Pages 1143-1150

  Jordan, Karin ^a   Sippel, Christoph ^a   Schmoll, Hans Joachim ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

5 HT3 serotonin receptor antagonists; Antiemetic therapy; ASCO antiemetic guidelines; MASCC antiemetic guidelines; NCCN practice antiemesis guidelines; Neurokinin1 receptor antagonist

Indexed keywords

ALTRETAMINE; ANTHRACYCLINE; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DAUNORUBICIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOLASETRON MESILATE; EPIRUBICIN; GRANISETRON; HYDROXYZINE; LOMUSTINE; LORAZEPAM; METOCLOPRAMIDE; NEUROKININ 1 RECEPTOR AGONIST; OLANZAPINE; ONDANSETRON; PALONOSETRON; PROCHLORPERAZINE; SEROTONIN 3 AGONIST; STEROID; TROPISETRON; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DYSPHORIA; EUPHORIA; HALLUCINATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; TREATMENT INDICATION;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; NAUSEA; PRACTICE GUIDELINES AS TOPIC; VOMITING;

EID: 35548934244     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.12-9-1143     Document Type: Review

References (30)

1. Herrstedt J. Nausea and emesis: Still an unsolved problem in cancer patients? Support Care Cancer 2002;10:85-87.
2. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 1999;17:2971-2994.
3. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol 1998;9:811-819.
4. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 2006;24:2932-2947.
5. Roila F, Hesketh PJ, Herrstedt J et al. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006;17:20-28.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis, V.1.2007. Available at http://www.nccn.org/ professionals/physician_gls/PDF/antiemesis.pdf. Accessed August 3, 2007.
7. Aapro MS, Molassiotis A, Olver I. Anticipatory nausea and vomiting. Support Care Cancer 2005;13:117-121.
8. Roila F, Donati D, Tamberi S et al. Delayed emesis: Incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 2002;10:88-95.
9. Einhorn LH, Brames MJ. Emetic potential of daily oral etoposide. Support Care Cancer 2006;14:1262-1265.
10. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 2005;13:80-84.
11. Jordan K, Grothey A, Kegel T et al. Antiemetic efficacy of an oral suspension of granisetron plus dexamethasone and influence of quality of life on risk for nausea and vomiting. Onkologie 2005;28:88-92.
12. 3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 2007 Jan 5; [Epub ahead of print].
13. 3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron. Cancer 2003;98:2473-2482.
14. Gralla R, Lichinitser M, Van Der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003;14:1570-1577.
15. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007;61:162-175.
16. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: Dosing, efficacy, and tolerability analysis. Ann Oncol 2007;18:233-240.
17. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-2830.
18. Italian Group for Antiemetic Research. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 2004;22:725-729.
19. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol 1998;16:2937-2942.
20. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-4119.
21. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-3098.
22. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-1006.
23. Nygren P, Hande K, Petty KJ et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:609-616.
24. Moreno I, Rosell R, Abad A et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer 1992;28A:1344-1347.
25. Kris MG, Gralla RJ, Tyson LB et al. Controlling delayed vomiting: Doubleblind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol 1989;7:108-114.
26. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005;23:1289-1294.
27. Bymaster FP, Calligaro DO, Falcone JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
28. Navari RM, Einhorn LH, Passik SD et al. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier Oncology Group study. Support Care Cancer 2005;13:529-534.
29. Navari RM, Einhorn LH, Loehrer PJ Sr et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study. Support Care Cancer 2007 Mar 21; [Epub ahead of print].
30. Aapro MS, Grunberg SM, Manikhas GM et al. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 2006;17:1441-1449.